Jiayan Zhu

Jiayan Zhu

Auto-generated profile, based on publicly available information

Jiayan Zhu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GZGuoying Zhou
Guoying Zhou
JZJiayan Zhu
Jiayan Zhu
LJLiang Jin
Liang Jin
JCJing Chen
Jing Chen
RXRuojiao Xu
Ruojiao Xu
HWHaitong Wan
Haitong Wan
Inflammatory dysfunction and angiogenesis inhibition are two main factors leading to the delayed healing of diabetic wounds. Hydrogels with anti-inflammatory and angiogenesis-promoting effects have been considered as promising wound care materials. Herein, a salvianolic acid B (SAB)-loaded hyaluronic acid (HA) self-healing hydrogel (HA/SAB) with anti-inflammatory and pro-angiogenesis capacities for diabetic wound healing is reported. The HA hydrogel was prepared via the covalent cross-linking of aldehyde groups in oxidized HA (OHA) and hydrazide groups in adipic dihydrazide (ADH)-modified HA (HA-ADH) with the formation of reversible acylhydrazone bonds. The obtained HA hydrogel exhibited multiple favorable properties such as porous structures, excellent self-healing properties, a sustainable release capacity of SAB, as well as excellent cytocompatibility. In addition, the effects of the SAB-loaded HA self-healing hydrogel were investigated via a full-thickness skin defect model using diabetic rats. The HA/SAB hydrogel showed enhanced skin regeneration effects with accelerated wound closure, shorter remaining dermal space length, thicker granulation tissue formation, and more collagen deposition. Furthermore, reduced inflammatory response and enhanced vascularization were found with HA/SAB2.5 hydrogel-treated wounds, indicating that the hydrogel promotes diabetic wound healing through the promotion of anti-inflammation and angiogenesis. Our results suggest that the fabricated SAB-loaded HA self-healing hydrogel is promising as a wound dressing for the treatment of diabetic wounds.

Verified
Journal Article
Open access
PDF file
YWYanying Wang
Yanying Wang
JZJiayan Zhu
Jiayan Zhu
JCJing Chen
Jing Chen
RXRuojiao Xu
Ruojiao Xu
Thomas GrothThomas Groth
Thomas Groth
GZGuoying Zhou
Guoying Zhou
Impaired healing of diabetic wounds harms patients’ quality of life and even leads to disability and death, which is an urgent issue to be solved clinically. Despite the great progress that has been achieved, it remains a worldwide challenge to develop effective therapeutic treatments for diabetic wounds. Recently, exosomes have attracted special attention because they can be involved in immune response, antigen presentation, cell migration, cell differentiation, tumor invasion and other processes. Meanwhile, exosomes have been proven to hold great potential in the treatment of diabetic wounds. Mechanistic studies of exosomes based on signaling pathways could not only help to uncover the mechanisms by which exosomes promote diabetic wound healing but could also provide a theoretical basis for the clinical application of exosomes. Herein, our mini-review aims to summarize the progress of research on the use of various exosomes derived from different cell types to promote diabetic wound healing, with a focus on the classical signaling pathways, including PI3K/Akt, Wnt, NF-κB, MAPK, Notch, Nrf2, HIF-1α/VEGF and TGF-β/Smad. The results show that exosomes could regulate these signaling pathways to down-regulate inflammation, reduce oxidative stress, increase angiogenesis, promote fibroblast proliferation, induce re-epithelization and inhibit scar formation, making exosomes attractive candidates for the treatment of diabetic wounds.

24 February 2023 in Polymers
Verified
Journal Article
Open access
PDF file
GZGuoying Zhou
Guoying Zhou
JZJiayan Zhu
Jiayan Zhu
CICatriona Inverarity
Catriona Inverarity
YFYifeng Fang
Yifeng Fang
ZZZhao Zhang
Zhao Zhang
JDJulian Francis Dye
Julian Francis Dye
In the search for a novel and scalable skin scaffold for wound healing and tissue regeneration, we fabricated a class of fibrin/polyvinyl alcohol (PVA) scaffolds using an emulsion templating method. The fibrin/PVA scaffolds were formed by enzymatic coagulation of fibrinogen with thrombin in the presence of PVA as a bulking agent and an emulsion phase as the porogen, with glutaraldehyde as the cross-linking agent. After freeze drying, the scaffolds were characterized and evaluated for biocompatibility and efficacy of dermal reconstruction. SEM analysis showed that the formed scaffolds had interconnected porous structures (average pore size e was around 330 µm) and preserved the nano-scale fibrous architecture of the fibrin. Mechanical testing showed that the scaffolds’ ultimate tensile strength was around 0.12 MPa with an elongation of around 50%. The proteolytic degradation of scaffolds could be controlled over a wide range by varying the type or degree of cross-linking and by fibrin/PVA composition. Assessment of cytocompatibility by human mesenchymal stem cell (MSC) proliferation assays shows that MSC can attach, penetrate, and proliferate into the fibrin/PVA scaffolds with an elongated and stretched morphology. The efficacy of scaffolds for tissue reconstruction was evaluated in a murine full-thickness skin excision defect model. The scaffolds were integrated and resorbed without inflammatory infiltration and, compared to control wounds, promoted deeper neodermal formation, greater collagen fiber deposition, facilitated angiogenesis, and significantly accelerated wound healing and epithelial closure. The experimental data showed that the fabricated fibrin/PVA scaffolds are promising for skin repair and skin tissue engineering.

1 November 2026 in Bioactive Materials
Verified
Journal Article
Open access
XSXiaohui Song
Xiaohui Song
JZJiayan Zhu
Jiayan Zhu
RWRouye Wang
Rouye Wang
YYYili Yao
Yili Yao
TZTinglian Zhou
Tinglian Zhou
Haijie HanHaijie Han
Haijie Han
Dry eye disease (DED) is a common ocular disorder that severely impairs daily life. Oxidative stress has been identified as a key pathogenic factor driving cellular senescence and corneal epithelial damage in DED. Herein, we developed a biocompatible supramolecular complex based on the host-guest interaction of TEMPO-modified β-cyclodextrin (TCD) and puerarin (Pue), designated as P@TCD, for managing DED. The P@TCD could mitigate the ROS accumulation, reduce DNA damage, promote cell cycle progression, and attenuate cellular senescence in the corneal epithelium, thus preventing the further deterioration of DED. In two DED mouse models, P@TCD demonstrated favorable therapeutic efficacy by reversing corneal epithelial defects, alleviating conjunctival damage, and accelerating lacrimal gland recovery, thereby restoring tear film homeostasis, especially improving tear film stability with TBUT values of more than 5.3 s, compared to the DED models of less than 2.8 s, which is even more than the Cycloome® of 3.7 s. These results suggested the considerable potential of this dual ROS scavenging strategy for the effective treatment of DED.